Novozymes Gelecekteki Büyüme

Future kriter kontrolleri 3/6

Novozymes kazanç ve gelirin sırasıyla yıllık 14.2% ve 6.8% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 14% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 8.6% olacağı tahmin edilmektedir.

Anahtar bilgiler

14.2%

Kazanç büyüme oranı

13.98%

EPS büyüme oranı

Chemicals kazanç büyümesi	15.9%
Gelir büyüme oranı	6.8%
Gelecekteki özkaynak getirisi	8.57%
Analist kapsamı	Good
Son güncelleme	10 Aug 2026

Gelecekteki son büyüme güncellemeleri

Recent updates

Anlatı Güncellemesi • Jul 24

NSIS B: Consumer Ingredients And Probiotics Expansion Will Support Higher Multiple Potential

The analyst price target for Novozymes has been reset to DKK 520, with analysts pointing to updated assumptions on growth, profitability and valuation multiples as the main drivers of the change. Analyst Commentary Recent Street research on Novozymes, now part of Novonesis, shows a series of constructive shifts in sentiment, with several firms revisiting their assumptions on valuation, execution and growth.

Anlatı Güncellemesi • Jul 10

NSIS B: Fair Outlook Will Rely On Probiotic Expansion In China

The analyst fair value estimate for Novozymes has been raised from DKK 380 to DKK 400, reflecting a series of higher Street price targets from multiple firms as analysts point to updated views on growth, margins and valuation for Novonesis. Analyst Commentary Recent Street research on Novozymes and Novonesis highlights a mix of optimism on long term potential and caution around execution and valuation risk.

Anlatı Güncellemesi • Jun 26

NSIS B: Consumer Ingredients And Probiotics Expansion Will Support Premium Multiple

Analysts have nudged the fair value estimate for Novozymes (Novonesis) slightly lower to DKK 548.58 from about DKK 560, reflecting a blend of trimmed Street price targets around DKK 552 and DKK 460, as well as updated assumptions for revenue growth, profit margins and a more conservative future P/E of 34x. Analyst Commentary Recent Street research on Novozymes reflects a mix of fine tuning on price targets and ratings, with bullish analysts focusing on the company’s positioning in consumer ingredients and its ability to support premium valuation metrics.

Analiz Makalesi • Jun 22

Novozymes (CPSE:NSIS B) Stock Could Be 31% Below Fair Value After UndoAge Deal

UndoAge partnership puts Novozymes (CPSE:NSIS B) in focus The new Memorandum of Understanding between UndoAge and Novonesis to co develop probiotics and postbiotics for the Chinese consumer health market puts fresh attention on Novozymes stock for investors tracking microbiome related opportunities. See our latest analysis for Novozymes. At a share price of DKK394.2, Novozymes has seen momentum build recently, with a 30 day share price return of 5.40% and a 90 day gain of 12.44%, even as the...

Kazanç ve Gelir Büyüme Tahminleri

CPSE:NSIS B - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (EUR Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2028	5,120	976	982	1,512	14
12/31/2027	4,772	856	819	1,387	15
12/31/2026	4,441	732	749	1,268	15
3/31/2026	4,199	597	774	1,282	N/A
12/31/2025	4,158	584	751	1,222	N/A
9/30/2025	4,142	547	745	1,123	N/A
6/30/2025	4,098	565	569	918	N/A
3/31/2025	4,058	459	586	950	N/A
12/31/2024	3,834	306	660	1,020	N/A
9/30/2024	3,471	314	634	941	N/A
6/30/2024	3,047	283	599	891	N/A
3/31/2024	2,636	334	422	692	N/A
12/31/2023	2,402	406	281	557	N/A
9/30/2023	2,390	430	169	485	N/A
6/30/2023	2,382	460	83	436	N/A
3/31/2023	2,390	487	83	476	N/A
12/31/2022	2,360	494	150	539	N/A
9/30/2022	2,268	460	206	554	N/A
6/30/2022	2,186	418	262	539	N/A
3/31/2022	2,090	416	337	530	N/A
12/31/2021	2,009	423	379	546	N/A
9/30/2021	1,958	427	461	593	N/A
6/30/2021	1,914	409	432	564	N/A
3/31/2021	1,883	389	443	577	N/A
12/31/2020	1,883	380	459	585	N/A
9/30/2020	1,920	415	442	521	N/A
6/30/2020	1,955	405	465	536	N/A
3/31/2020	1,968	439	407	482	N/A
12/31/2019	1,924	422	N/A	428	N/A
9/30/2019	1,923	411	N/A	460	N/A
6/30/2019	1,917	434	N/A	505	N/A
3/31/2019	1,922	417	N/A	477	N/A
12/31/2018	1,927	432	N/A	493	N/A
9/30/2018	1,924	427	N/A	515	N/A
6/30/2018	1,915	429	N/A	490	N/A
3/31/2018	1,920	423	N/A	501	N/A
12/31/2017	1,952	419	N/A	546	N/A
9/30/2017	1,958	421	N/A	533	N/A
6/30/2017	1,934	412	N/A	522	N/A
3/31/2017	1,919	414	N/A	547	N/A
12/31/2016	1,902	410	N/A	517	N/A
9/30/2016	1,864	394	N/A	488	N/A
6/30/2016	1,883	394	N/A	437	N/A
3/31/2016	1,883	384	N/A	450	N/A
12/31/2015	1,876	378	N/A	447	N/A
9/30/2015	1,840	366	N/A	395	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: NSIS B 'nin tahmini kazanç büyümesi (yıllık 14.2% ) tasarruf oranının ( 2.1% ) üzerindedir.

Kazançlar ve Piyasa: NSIS B şirketinin kazançlarının (yıllık 14.2% ) Danish pazarından (yıllık 8.2% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: NSIS B şirketinin kazançlarının artması bekleniyor, ancak önemli ölçüde.

Gelir ve Pazar: NSIS B şirketinin gelirinin (yıllık 6.8% ) Danish pazarından (yıllık 3.9% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: NSIS B şirketinin gelirinin (yıllık 6.8% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: NSIS B 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 8.6 %).

Büyüyen şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/08/10 00:56
Gün Sonu Hisse Fiyatı	2026/08/10 00:00
Kazançlar	2026/03/31
Yıllık Kazançlar	2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Novozymes A/S 28 Bu analistlerden 15, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Cezara Lozneanu	Barclays
Alexander Sloane	Barclays
Sebastian Satz	Barclays

Novozymes Gelecekteki Büyüme

Future kriter kontrolleri 3/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Novozymes A/S Revises Earnings Guidance for the Year 2025

Consensus EPS estimates fall by 20%

Consensus EPS estimates increase by 15%

Novonesis A/S Maintains Earnings Guidance for the Year 2025

Consensus EPS estimates fall by 12%

Consensus EPS estimates increase by 11%

Recent updates

NSIS B: Consumer Ingredients And Probiotics Expansion Will Support Higher Multiple Potential

NSIS B: Fair Outlook Will Rely On Probiotic Expansion In China

NSIS B: Consumer Ingredients And Probiotics Expansion Will Support Premium Multiple

Novozymes (CPSE:NSIS B) Stock Could Be 31% Below Fair Value After UndoAge Deal

First quarter 2026 earnings: EPS exceeds analyst expectations

Novozymes Delivers 7% Organic Sales Growth and Expands Capacity in Q1 2026

Novonesis A/S Approves Dividend on A and B Share

Upcoming dividend of kr.4.25 per share

Full year 2025 earnings: EPS misses analyst expectations

Dividend of kr.4.25 announced

Vice Chair of the Board recently bought kr.1.0m worth of stock

Novozymes A/S, Annual General Meeting, Mar 23, 2026

Novozymes A/S Proposes Dividend for Full Year 2025

Now 21% overvalued

Third quarter 2025 earnings: EPS misses analyst expectations

Novozymes A/S Revises Earnings Guidance for the Year 2025

Consensus EPS estimates fall by 20%

Now 20% undervalued after recent price drop

Vice Chair of the Board recently bought kr.1.2m worth of stock

First half dividend of kr.2.25 announced

Consensus EPS estimates increase by 15%

New minor risk - Dividend sustainability

Novonesis A/S Approves Interim Dividend for First Half of 2025

Now 20% undervalued

New major risk - Revenue and earnings growth

Novonesis A/S (CPSE:NSIS B) completed the acquisition of remaining 50% stake in Feed Enzymes Alliance from DSM-Firmenich AG (ENXTAM:DSFIR).

First quarter 2025 earnings: EPS exceeds analyst expectations

Novonesis A/S Maintains Earnings Guidance for the Year 2025

Less than half of directors are independent

Novonesis A/S to Report Fiscal Year 2025 Results on Feb 25, 2026

Now 24% undervalued after recent price drop

Novonesis A/S Approves Election of Monila Kothari as A Director and Composition of the Board of Directors and Its Committees

Now 20% undervalued after recent price drop

New minor risk - Dividend sustainability

Novonesis A/S Announces Board Changes

Full year 2024 earnings: EPS misses analyst expectations

Novonesis A/S Proposes Dividend, Payable on April 8, 2025

Novonesis Announces Jacob Vishof Paulsen Will Leave His Position as Executive Vice President of Food & Beverage Biosolutions, Effective March 31, 2025

Novonesis A/S Announces That Sharon James Will Not Be Seeking Re-Election to the Board of Directors, Effectively on December 31, 2024

Novonesis A/S to Report First Half, 2025 Results on Aug 13, 2025

Novonesis A/S Announces Board Changes

Consensus EPS estimates fall by 12%

Consensus EPS estimates increase by 11%

Consensus EPS estimates fall by 20%

First half 2024 earnings released: EPS: €0.14 (vs €0.67 in 1H 2023)

Novonesis Approves Interim Dividend for 2024, Payable on September 3, 2024

Consensus EPS estimates increase by 13%, revenue downgraded

Novonesis Provides Sales Guidance for the Year 2024

Novozymes A/S Approves Dividend for the Last Four Months Ended December 31, 2023

Upcoming dividend of kr.2.00 per share

Novozymes A/S Proposes Dividend for the Last Four Months Ended December 31, 2023

Novonesis Provides Earnings Guidance for the Year 2024

Novonesis to Unveil Fit-for-Food Mood-Support Probiotic at Natural Product Expo West

Novozymes A/S Announces Board Appointments

Consensus EPS estimates increase by 13%

Consensus EPS estimates increase by 13%

Consensus EPS estimates increase by 13%

Consensus EPS estimates increase by 13%

Consensus EPS estimates increase by 13%

Novozymes A/S to Report First Half, 2024 Results on Aug 28, 2024

Consensus EPS estimates increase by 14%

Full year 2023 earnings: Revenues in line with analyst expectations

New major risk - Shareholder dilution

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S to Report Fiscal Year 2023 Final Results on Apr 08, 2024

Novozymes Launches ProSilience™ HU58

Third quarter 2023 earnings: Revenues exceed analyst expectations

Novozymes A/S Approves Interim Dividend, Payable on October 17, 2023

Novozymes A/S and Chr. Hansen Announce Executive Leadership Team and Organizational Structure